

# Kazuki Matsui

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/602578/publications.pdf>

Version: 2024-02-01

13  
papers

395  
citations

1040056

9  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

407  
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-6-mediated Th17 differentiation through ROR $\gamma$ t is essential for the initiation of experimental autoimmune myocarditis. <i>Cardiovascular Research</i> , 2011, 91, 640-648.	3.8	72
2	In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 76, 203-212.	4.0	64
3	<i>In Vitro</i> Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting <i>In Vivo</i> Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents. <i>Molecular Pharmaceutics</i> , 2015, 12, 2418-2428.	4.6	53
4	The Evaluation of <i>In Vitro</i> Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2804-2814.	3.3	48
5	The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS). <i>European Journal of Pharmaceutical Sciences</i> , 2017, 102, 126-139.	4.0	44
6	Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Journal of Pharmaceutical Sciences</i> , 2018, 115, 258-269.	4.0	43
7	Utilization of Gastrointestinal Simulator, an in Vivo Predictive Dissolution Methodology, Coupled with Computational Approach To Forecast Oral Absorption of Dipyridamole. <i>Molecular Pharmaceutics</i> , 2017, 14, 1181-1189.	4.6	26
8	Cathelicidin antimicrobial peptide inhibits fibroblast migration via P2X7 receptor signaling. <i>Biochemical and Biophysical Research Communications</i> , 2013, 437, 609-614.	2.1	12
9	The Provisional No-Effect Threshold of Sugar Alcohols on Oral Drug Absorption Estimated by Physiologically Based Biopharmaceutics Model. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 467-477.	3.3	11
10	In Vitro Sensitivity Analysis of the Gastrointestinal Dissolution Profile of Weakly Basic Drugs in the Stomach-to-Intestine Fluid Changing System: Explanation for Variable Plasma Exposure after Oral Administration. <i>Molecular Pharmaceutics</i> , 2021, 18, 1711-1719.	4.6	8
11	Transverse comparison of mannitol content in marketed drug products: Implication for no-effect dose of sugar alcohols on oral drug absorption. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 57, 101728.	3.0	6
12	Bioequivalence of Oral Drug Products in the Healthy and Special Populations: Assessment and Prediction Using a Newly Developed In Vitro System $\hat{\rho}$ BE Checker $\hat{\rho}$ . <i>Pharmaceutics</i> , 2021, 13, 1136.	4.5	6
13	Potential pharmacokinetic interaction between orally administered drug and osmotically active excipients in pediatric polypharmacy. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 165, 105934.	4.0	2